BackJazz Pharmaceuticals plc Overview

Jazz Pharmaceuticals plc Other Current Assets

Jazz Pharmaceuticals plc's other current assets is $440M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$435.00M
6.07% YoYΔ $24.90M vs prior year quarter

Peer average

Loading

Jazz Pharmaceuticals plc Other Current Assets History

Loading

Jazz Pharmaceuticals plc vs. peers: Other Current Assets Comparison

Loading

Jazz Pharmaceuticals plc Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Jazz Pharmaceuticals plc (JAZZ) FAQ

The latest other current assets for JAZZ is $440M as of March 2026. That compares with $410M in the prior-year period — up 6.1% year over year. Investors often review this figure alongside Jazz Pharmaceuticals plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, JAZZ's other current assets moved from $410M to $440M — a 6.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jazz Pharmaceuticals plc's operating scale or balance-sheet position.

A other current assets figure of $440M for JAZZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting JAZZ's other current assets ($440M), review year-over-year change from $410M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Jazz Pharmaceuticals plc's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.